Marina Bianchi1, Antonio Clavenna, Maurizio Bonati. 1. Laboratory for Mother and Child Health, Department of Public Health, Mario Negri Pharmacological Research Institute, via G. La Masa 19, 20156 Milan, Italy. marina.bianchi@marionegri.it
Abstract
OBJECTIVE: The objective of this study was to analyse inter-and intra-country quantitative and qualitative differences in anti-asthmatic prescriptions to children and adolescents. METHODS: A literature search was performed in EMBASE and MEDLINE to identify pharmaco-epidemiological studies published from January 1, 2000 to December 31, 2008 in which anti-asthmatic prescription prevalence in out-hospital children was measured. A meta-analytic weighted average and 95% confidence intervals of prescription prevalences were calculated using a random-effect(s) model. Inter- and intra-country quantitative and, where possible, qualitative prescribing patterns were compared and assessed. RESULTS: Twelve studies were identified (ten from Europe, one from Canada and one from the USA), but epidemiological indicators varied widely, and only eight were suitable for meta-analysis. The data from these studies revealed inter-country quantitative differences in prescription prevalences in the overall population <or=19 years, with Italy having a prescription prevalence of 19.0%, Canada, 18.0%, USA, 14.6%, Denmark, 13.9%, Norway, 9.1% and the Netherlands, 6.2%. The overall prevalence was 13.3%. The analysis of qualitative inter-country differences revealed that, except for Italy, inhalatory short-acting beta-agonists were the most prescribed, followed by inhalatory corticosteroids. CONCLUSIONS: This first overall analysis of anti-asthmatic utilization studies in out-of-hospital children indicates a wide variability in anti-asthmatic prescription prevalence. It also reveals that epidemiological evaluations should be improved by using homogeneous indicators and, in order to validate the use of anti-asthmatic prescription as a proxy of disease, the diagnosis of asthma should accompany the data of prescriptions within the same population.
OBJECTIVE: The objective of this study was to analyse inter-and intra-country quantitative and qualitative differences in anti-asthmatic prescriptions to children and adolescents. METHODS: A literature search was performed in EMBASE and MEDLINE to identify pharmaco-epidemiological studies published from January 1, 2000 to December 31, 2008 in which anti-asthmatic prescription prevalence in out-hospital children was measured. A meta-analytic weighted average and 95% confidence intervals of prescription prevalences were calculated using a random-effect(s) model. Inter- and intra-country quantitative and, where possible, qualitative prescribing patterns were compared and assessed. RESULTS: Twelve studies were identified (ten from Europe, one from Canada and one from the USA), but epidemiological indicators varied widely, and only eight were suitable for meta-analysis. The data from these studies revealed inter-country quantitative differences in prescription prevalences in the overall population <or=19 years, with Italy having a prescription prevalence of 19.0%, Canada, 18.0%, USA, 14.6%, Denmark, 13.9%, Norway, 9.1% and the Netherlands, 6.2%. The overall prevalence was 13.3%. The analysis of qualitative inter-country differences revealed that, except for Italy, inhalatory short-acting beta-agonists were the most prescribed, followed by inhalatory corticosteroids. CONCLUSIONS: This first overall analysis of anti-asthmatic utilization studies in out-of-hospital children indicates a wide variability in anti-asthmatic prescription prevalence. It also reveals that epidemiological evaluations should be improved by using homogeneous indicators and, in order to validate the use of anti-asthmatic prescription as a proxy of disease, the diagnosis of asthma should accompany the data of prescriptions within the same population.
Authors: Michelle M Cloutier; Dorothy B Wakefield; Pamela Sangeloty-Higgins; Steven Delaronde; Charles B Hall Journal: Pediatrics Date: 2006-11 Impact factor: 7.124
Authors: A Afonso; S Schmiedl; C Becker; S Tcherny-Lessenot; P Primatesta; E Plana; P Souverein; Y Wang; J C Korevaar; J Hasford; R Reynolds; M C H de Groot; R Schlienger; O Klungel; M Rottenkolber Journal: Eur J Clin Pharmacol Date: 2016-05-24 Impact factor: 2.953
Authors: Marietta Rottenkolber; Rainald Fischer; Luisa Ibáñez; Joan Fortuny; Robert Reynolds; Justyna Amelio; Roman Gerlach; Martin Tauscher; Petra Thürmann; Joerg Hasford; Sven Schmiedl Journal: BMC Pulm Med Date: 2015-05-06 Impact factor: 3.317
Authors: Marietta Rottenkolber; Eef Voogd; Liset van Dijk; Paola Primatesta; Claudia Becker; Raymond Schlienger; Mark C H de Groot; Yolanda Alvarez; Julie Durand; Jim Slattery; Ana Afonso; Gema Requena; Miguel Gil; Arturo Alvarez; Ulrik Hesse; Roman Gerlach; Joerg Hasford; Rainald Fischer; Olaf H Klungel; Sven Schmiedl Journal: PLoS One Date: 2015-02-23 Impact factor: 3.240
Authors: Sven Schmiedl; Rainald Fischer; Luisa Ibáñez; Joan Fortuny; Olaf H Klungel; Robert Reynolds; Roman Gerlach; Martin Tauscher; Petra Thürmann; Joerg Hasford; Marietta Rottenkolber Journal: PLoS One Date: 2014-09-02 Impact factor: 3.240